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ABSTRACT
p16 is a negative regulator of cell proliferation and is considered a tumor 
suppressor protein. Alterations in p16 protein expression are associated with tumor 
development and progression. However, the p16 expression status in the peritumoral 
stroma has not been investigated in the endometrium. Therefore, we evaluated stromal 
p16 expression in different types of endometrial lesions using immunohistochemistry. 
Differences in the p16 expression status according to the degree of malignancy 
and histological type were analyzed. This study included 62, 26, and 36 cases of 
benign, precancerous, and malignant endometrial lesions, respectively. Most 
benign lesions showed negative or weak expression, whereas precancerous lesions 
showed a variable degree of staining proportion and intensity. Atypical hyperplasia/
endometrial intraepithelial neoplasia (AH/EIN) and serous endometrial intraepithelial 
carcinoma (SEIC) had significantly higher stromal p16 expression levels than benign 
lesions. Endometrioid carcinoma (EC), serous carcinoma (SC), and carcinosarcoma 
showed significantly elevated stromal p16 expression levels compared with benign 
and precancerous lesions. In addition, there were significant differences in stromal 
p16 expression between AH/EIN and SEIC and between EC and SC. In contrast, 
differences in stromal p16 expression among nonpathological endometrium, atrophic 
endometrium, endometrial polyp, and hyperplasia without atypia were not statistically 
significant. Our observations suggest that stromal p16 expression is involved in the 
development and progression of endometrial carcinoma, and raise the possibility that 
p16 overexpression in the peritumoral stroma is associated with aggressive oncogenic 
behavior of endometrial SC.
INTRODUCTION
Endometrial carcinoma is the commonest pelvic 
gynecological cancer in the westernized parts of the world 
[1, 2]. Worldwide, the incidence of endometrial carcinoma 
is rapidly increasing, with the highest disease burden 
reported in North America and Western Europe. In the 
United States, if current trends continue, then there will 
be a doubling in the number of women diagnosed with 
endometrial carcinoma by the year 2030 to 122,000 cases 
per year [1, 3]. These trends have extended globally. In 
particular, Korea has witnessed a doubling of the age-
standardized incidence of endometrial carcinoma [4, 5].
p16 is the principal member of the INK4 family 
of cyclin-dependent kinase (CDK) inhibitors [6]. As a 
regulatory protein of the cell cycle, p16 is involved in 
G1-to-S phase transition. Upon binding to CDK4/6, p16 
inhibits the cyclin D1-CDK4/6 complex formation and 
CDK4/6-mediated phosphorylation of the retinoblastoma 
(RB) protein. Once RB is phosphorylated, the E2F-RB 
complex dissociates, leading to reduced growth-suppressor 
activity of RB [7]. Like RB protein, p16 is a tumor 
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suppressor. p16 maintains RB protein family members in 
a hypophosphorylated state [7–10]. However, it is difficult 
to explain many aspects of p16 function and regulation 
by its well-known function as a tumor suppressor alone. 
In addition, the molecular pathways responsible for p16 
function and expression have not yet been elucidated.
p16 expression has been analyzed in some studies 
of gynecological malignancy. According to the 2014 
World Health Organization (WHO) Classification, more 
than half of ovarian high-grade serous carcinomas show 
diffuse, strong p16 expression [11]. The majority of 
endometrial serous carcinoma (SC) also strongly expresses 
p16 protein. p16 and p53 expression levels are used as 
differential immunostaining markers to distinguish high-
grade serous carcinoma from other histological types of 
ovarian carcinoma and SC from other histological types 
of endometrial carcinoma. In addition, p16 overexpression 
occurs in human papillomavirus (HPV)-related tumors 
[6, 11]. p16 overexpression indicates high-risk HPV 
infection, not only in uterine cervical squamous cell 
carcinoma and usual-type endocervical adenocarcinoma, 
but also in endocervical adenocarcinoma in situ and 
high-grade squamous intraepithelial lesions of the vulva, 
vagina, and anogenital regions. Therefore, p16 is used 
as a diagnostic biomarker for HPV-related precancerous 
lesions and invasive carcinoma [6, 12].
However, conflicting patterns of p16 expression 
have been reported, which further complicates the 
understanding of its biological and pathological roles. 
p16 expression is either lost or downregulated [13–16], 
or clearly overexpressed [17–21], in different types of 
malignancy. Recently, during the routine diagnosis of 
surgically resected or curetted endometrial neoplasms, 
we noticed p16 expression in the peritumoral stroma, as 
well as in the glandular epithelial cells. The levels of p16 
expression in the stromal cells varied depending on the 
degree of malignancy and histological type of endometrial 
lesions. Although p16 is commonly used as a biomarker 
for diagnosing gynecological malignancies, its expression 
in the stromal component of endometrial neoplasms has 
seldom been studied. In this study, we examined stromal 
p16 expression in benign, precancerous, and malignant 
endometrial neoplasms using immunohistochemical 
staining and investigated whether a significant difference 
exists in stromal p16 immunoreactivity according to the 
degree of malignancy and/or histological type.
RESULTS
Patient demographics
This preliminary study was conducted with 124 
patients who underwent curettage, polypectomy, or 
hysterectomy for benign, precancerous, or malignant 
lesions of the endometrium from March 2015 to May 
2016. Classification of all 124 cases according to the 
degree of malignancy of endometrial lesions resulted 
in 62 benign lesions, 26 precancerous lesions, and 
36 malignant lesions. The age of the patients ranged from 
25 to 74 years (median, 46 years) in patients with benign 
lesions, from 27 to 67 years (median, 51 years) in patients 
with precancerous lesions, and from 41 to 84 years 
(median, 59 years) in patients with malignant lesions. 
According to histological type, the 62 benign lesions 
consisted of nonpathological endometrium (10 cases), 
atrophic endometrium (13 cases), adenomyosis (8 cases), 
endometrial polyp (17 cases), and hyperplasia without 
atypia (14 cases). The 26 precancerous lesions consisted of 
atypical hyperplasia/endometrial intraepithelial neoplasia 
(AH/EIN; 21 cases) and serous endometrial intraepithelial 
carcinoma (SEIC; 5 cases). The 36 malignant lesions 
consisted of endometrioid carcinoma (EC; 21 cases), SC 
(8 cases), and carcinosarcoma (7 cases).
Stromal p16 expression in benign, precancerous, 
and malignant endometrial lesions
The p16 immunostaining scores of benign, 
borderline, and malignant endometrial lesions are presented 
in Table 1. Representative photomicrographs of stromal 
p16 expression in benign endometrial lesions are presented 
in Figure 1. All 62 cases of benign endometrial neoplasm 
showed p16 immunostaining scores of ≤ 3. p16-positive 
stromal cells were randomly distributed throughout the 
entire endometrial thickness. There was no significant 
difference in stromal p16 expression between the surface 
and basal endometrium. Of the 62 cases of benign lesions, 
33 cases (53.2%) showed no p16 expression, whereas 16 
cases (25.8%), 10 cases (16.1%), and 3 cases (4.8%) had 
scores of 1, 2, and 3, respectively. Two (11.8%) and one 
(7.1%) cases of endometrial polyp and hyperplasia without 
atypia, respectively, exhibited scores of 3. No significant 
difference was observed in stromal p16 expression status 
among the histological types (P = 0.135). Of the 10 cases 
of nonpathological endometrium, two cases (20.0%) 
were found to have regional heterogeneity in stromal 
p16 expression. In both cases, approximately one-half of 
the stromal cells displayed weak p16 immunoreactivity 
(score 2). In the majority of benign endometrial lesions, the 
endometrial glandular epithelium displayed patchy, weak to 
moderate cytoplasmic p16 immunoreactivity. p16-positive 
endometrial glands were randomly distributed throughout 
the entire endometrium.
Representative photomicrographs of stromal p16 
expression in precancerous endometrial lesions are 
presented in Figure 2. Of the 26 cases of precancerous 
endometrial lesions, 18 (69.2%) showed p16 
immunostaining scores of ≥ 3. Six (28.6%) and two (9.5%) 
cases of AH/EIN had scores of 4 and 6, respectively. While 
the scores of AH/EIN varied from 0 to 6, those of SEIC were 
≥ 4. Four (80.0%) of the 5 SEIC cases showed scores of ≥ 6. 
In contrast with the benign lesions, there was a significant 
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difference in stromal p16 expression status between AH/
EIN and SEIC (P = 0.001); stromal p16 expression was 
significantly higher in SEIC than in AH/EIN. All cases 
of SEIC exhibited strong p16 staining intensity in almost 
all of the tumor cells, whereas none of the AH/EIN cells 
showed diffuse expression. Fifteen (71.4%) of the 21 AH/
EIN cases exhibited patchy, weak to moderate cytoplasmic 
p16 immunoreactivity in the tumor cells.
Representative photomicrographs of stromal p16 
expression in malignant endometrial lesions are presented 
in Figure 3 (EC and SC) and Figure 4 (carcinosarcoma). 
Of the 36 cases of malignant endometrial lesions, 29 cases 
(80.6%) showed p16 immunostaining scores of ≥ 4. All of 
the remaining 7 cases with scores of ≤ 3 were EC; none of 
the cases of SC or carcinosarcoma displayed scores of ≤ 3. 
Moreover, 7 (87.5%) of the 8 SC cases and 6 (85.7%) of the 
7 carcinosarcoma cases showed scores of ≥ 6. In contrast, in 
EC, 10 (47.6%) of the 21 cases had scores of ≥ 6. Stromal p16 
expression levels were significantly higher in SC than in EC 
(P = 0.021), whereas the difference between carcinosarcoma 
and SC was not statistically significant (P = 0.483).
Differences in stromal p16 expression 
between benign, precancerous, and malignant 
endometrial lesions
The median p16 immunostaining scores of benign, 
precancerous and malignant endometrial lesions were 
0, 3.5, and 6, respectively. To analyze the differences 
in stromal p16 expression between groups classified 
according to the degree of malignancy, a linear-by-linear 
association test was performed (Table 2). A significant 
difference was observed in stromal p16 expression 
between the benign and precancerous lesions (P < 0.001). 
Moreover, stromal p16 expression differed significantly 
between the precancerous and malignant groups 
(P = 0.005).
We classified endometrial lesions into two 
clusters based on the histological type and degree of 
malignancy. The first cluster consisted of nonpathological 
endometrium, endometrial polyp, hyperplasia without 
atypia, AH/EIN, and EC (Table 3). Stromal p16 
expression levels were not significantly different between 
nonpathological endometrium and endometrial polyp 
(P = 0.457). Similarly, stromal p16 expression levels in 
hyperplasia without atypia were not significantly different 
from nonpathological endometrium or endometrial polyp 
(P = 0.920). In contrast, AH/EIN exhibited significantly 
higher levels of stromal p16 expression compared with 
hyperplasia without atypia (P < 0.001). A significant 
difference was also noted in stromal p16 expression when 
comparing EC with AH/EIN (P = 0.012).
The second cluster consisted of atrophic 
endometrium, endometrial polyp, SEIC, and SC (Table 4). 
SC generally arises in the setting of an atrophic, and not 
a hyperplastic, endometrium or an endometrial polyp 
Table 1: Stromal p16 expression in benign, precancerous, and malignant endometrial lesions
Category Pathological 
diagnosis
Total p16 immunostaining score
0 1 2 3 4 6 9
Benign Nonpathological 
endometrium
10 5 (50.0) 3 (50.0) 2 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Atrophic 
endometrium
13 9 (69.2) 3 (23.1) 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Adenomyosis 8 6 (75.0) 0 (0.0) 2 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Endometrial 
polyp
17 8 (47.1) 3 (17.6) 4 (23.5) 2 (11.8) 0 (0.0) 0 (0.0) 0 (0.0)
Hyperplasia 
without atypia
14 5 (35.7) 7 (50.0) 1 (7.1) 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0)
Precancerous AH/EIN 21 1 (4.8) 3 (14.3) 4 (19.0) 5 (23.8) 6 (28.6) 2 (9.5) 0 (0.0)
SEIC 5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 2 (40.0) 2 (40.0)
Malignant Endometrioid 
carcinoma
21 2 (9.5) 0 (0.0) 1 (4.8) 4 (19.0) 4 (19.0) 7 (33.3) 3 (14.3)
Serous carcinoma 8 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (12.5) 3 (37.5) 4 (50.0)
Carcinosarcoma 7 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (14.3) 4 (57.1) 2 (28.6)
Abbreviations: AH/EIN: atypical hyperplasia/endometrioid intraepithelial neoplasia, SEIC: serous endometrial 
intraepithelial carcinoma
Oncotarget4829www.impactjournals.com/oncotarget
[11]. No significant difference in stromal p16 expression 
was observed between atrophic endometrium and 
endometrial polyp, even though there was a trend toward 
increased expression in endometrial polyp (P = 0.088). 
SEIC exhibited significantly higher levels of stromal 
p16 expression compared with atrophic endometrium or 
endometrial polyp (P < 0.001). All cases of SEIC showed 
scores of ≥ 4, whereas all cases of atrophic endometrium 
and endometrial polyp showed scores of ≤ 3. In contrast 
with the endometrioid type, there was no statistically 
significant difference in stromal p16 expression between 
SEIC and SC (P = 0.788).
DISCUSSION
A novel finding reported in this preliminary 
study is the gradual and significant increase in stromal 
p16 expression with increased degree of malignancy 
in benign, precancerous, and malignant endometrial 
lesions. We observed that more than 90% (59/62) of the 
benign lesions had p16 immunostaining scores of < 3, 
whereas the precancerous lesions showed scores of 3 to 
6 in approximately 60% (16/26) of the cases examined. 
Moreover, more than half (23/36) of malignant lesions 
displayed scores of 6 or more. Consistent with this 
finding, a comparison of p16 expression within tumors 
of each histological type also revealed significant 
differences. In endometrioid neoplasms, the differences 
in stromal p16 expression between precancerous and 
benign lesions (P < 0.001) and between malignant and 
precancerous lesions (P = 0.012) were statistically 
significant. Also in serous neoplasms, stromal p16 
expression was significantly higher in malignant and 
precancerous lesions than in benign lesions (P < 0.001). 
In addition, stromal p16 expression was found to have 
100% sensitivity and 100% specificity when the cutoff 
Figure 1: Stromal p16 expression in benign endometrial lesions. A. Nonpathological endometrium. White arrows indicate 
endometrial stroma. B. The endometrial stromal cells (white arrows) do not exhibit p16 immunoreactivity, whereas the endometrial 
glandular epithelium (black arrows) displays patchy p16 expression, with variable staining intensities. C. Atrophic endometrium. D. The 
glandular epithelium (black arrows) exhibits scattered p16 immunoreactivity, whereas in the stroma (white arrows), p16 expression is 
absent. E. Adenomyosis. White arrows indicate endometrial stroma. F. This adenomyotic focus has an identical p16 expression pattern to 
that of nonpathological endometrium. None of the stromal cells (white arrows) reacts with p16 protein. Note scattered p16 immunoreactivity 
in the glandular epithelium (black arrows). G. Endometrial polyp. The presence of thick-walled blood vessels is a characteristic finding of 
endometrial polyp. H. A few scattered stromal cells exhibit weak to moderate p16 immunoreactivity. I. Endometrial polyp. J. In contrast 
with image H, approximately one-half of stromal cells display moderate p16 immunoreactivity. K. Hyperplasia without atypia. L. The 
stromal p16 expression level in hyperplasia without atypia is similar to that in endometrial polyp (image H).
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value is p16 immunostaining score 4 (Table 5). These 
findings are consistent with those of our previous study 
demonstrating stromal p16 overexpression in ovarian 
carcinoma [21]. Compared with benign and borderline 
ovarian neoplasms, ovarian carcinomas had significantly 
elevated p16 expression levels in the peritumoral stroma. 
These significances remained when the analysis was 
performed based on lesion classification as serous, 
mucinous, and endometriosis-associated neoplasms. Our 
observation of significantly higher levels of stromal p16 
expression in malignant endometrial lesions suggests that 
p16 may be involved in tumor cell growth and invasion in 
the tumor microenvironment through its overexpression 
in stromal cells. Some previous studies have reported p16 
Figure 2: Stromal p16 overexpression in precancerous endometrial lesions: Atypical hyperplasia/endometrioid 
intraepithelial hyperplasia (AH/EIN) and serous endometrial intraepithelial carcinoma (SEIC). A. AH/EIN. B. A few 
scattered stromal cells exhibit weak to moderate p16 immunoreactivity. C. AH/EIN. D. None of the stromal cells reacts with p16 protein. 
Note scattered p16 immunoreactivity in the glandular epithelium. E. SEIC. Serous carcinoma (SC) is present at the right upper corner. 
Black arrows indicate SEIC, which locates adjacent to the SC. F. High-power view (×200) of SEIC (black arrows) displays a single 
layer of neoplastic epithelial cells showing severe nuclear pleomorphism. The stromal cells are irregularly distributed and admixed with 
inflammatory cells. G. The tumor cells strongly react with p16. The stromal cells also display diffuse, moderate p16 immunoreactivity.
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overexpression at the invasive tumor front of endometrial 
carcinoma, colorectal carcinoma, and basal cell carcinoma 
[22–25]. These results suggest that p16 may be involved in 
tumor invasion and progression and support the hypothesis 
that the p16 protein promotes invasiveness through 
interactions with other molecules related with tumor cell 
migration and invasion [6, 22–24, 26]. To confirm our 
preliminary results, it will be necessary to analyze stromal 
p16 expression using a larger number of endometrial 
carcinoma samples.
We demonstrated that stromal p16 expression 
was significantly higher in endometrial SC than in 
endometrial EC. Seven of the 8 (87.5%) of SC cases 
showed p16 immunostaining scores of ≥ 6, whereas 
52.4% (11/21) of the EC cases had scores of ≤ 4. The 
majority of endometrial SC displayed diffuse, strong p16 
expression. In addition to p53 protein, which typically 
shows aberrant expression pattern in SC, p16 is also used 
as a diagnostic biomarker for differentiating EC from 
SC. The characteristic immunohistochemical findings of 
endometrial SC, such as diffuse, strong p16 expression and 
aberrant p53 expression, are observed in the tumor cells. 
However, there has been no report about the expression 
pattern of p16 and p53 proteins in the peritumoral stroma 
of SC. Our observation suggests that the significantly 
higher p16 expression levels in SC compared with EC 
may reflect the more aggressive oncogenic behavior, 
such as invasiveness, metastatic ability, and recurrence, 
and worse prognosis of SC compared with those of EC. 
Consistent with this finding, SEIC showed significantly 
higher stromal p16 expression levels than AH/EIN. 
SEIC, a putative precursor of SC, can be associated with 
intra-abdominal carcinoma. In other words, even in the 
absence of definitive invasion in the uterus, SEIC can 
behave like SC and result in peritoneal carcinomatosis. 
Our observation suggests that the significantly higher p16 
expression levels in SEIC compared with AH/EIN may 
reflect the more aggressive nature of SEIC compared with 
that of AH/EIN.
We also demonstrated that stromal p16 expression 
levels are significantly higher in carcinosarcoma than in 
EC, but not in SC. Histopathologically, EC corresponds to 
Figure 3: Stromal p16 overexpression in malignant endometrial lesions: Endometrioid carcinoma (EC) and serous 
carcinoma (SC). A. EC. White arrows indicate the periglandular stroma. B. p16 strongly highlights the spindle-shaped stromal cells 
(white arrows) that are distributed between neoplastic glands. The tumor cells (black arrows) show patchy p16 expression. C. SC. D. Both 
the tumor cells and stroma exhibit diffuse, strong p16 immunoreactivity.
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type I endometrial carcinoma, whereas SC is the prototype 
of type II endometrial carcinoma. Carcinosarcoma is also 
considered as a type II endometrial carcinoma. Type I 
endometrial carcinoma develops from normal endometrial 
glandular epithelium under the influence of estrogenic 
stimulation, through a continuum of histopathologically 
recognizable endometrial hyperplasia. The overall survival 
rate for patients with type I endometrial carcinoma 
exceeds 80%. In contrast, type II endometrial carcinoma is 
known to be unrelated to estrogenic stimulation and have 
an aggressive behavior. Such lesions are characterized by 
deep myometrial invasion, frequent nodal and extrauterine 
metastases, and poor outcome; approximately 50% of 
patients with type II endometrial carcinoma develop 
recurrences [27]. A significant difference in stromal p16 
expression levels between type I and II endometrial 
carcinomas raises the possibility that the aggressive 
oncogenic behavior of type II lesions may be associated 
with p16 overexpression in the peritumoral stroma.
We found one previous study reporting stromal 
p16 expression in endometrial neoplastic lesions [28]. 
For 80.0% (28/35) of endometrial polyp cases, p16 
immunoreactivity with moderate or greater intensity was 
observed in fibrous stroma, and 1 (3.0%; 1/33) case of 
endometrial hyperplasia showed weak p16 expression; 
however, none of the endometrial carcinoma cases (0.0%; 
0/23) showed stromal p16 expression. Moritani et al. [28] 
stated that stromal p16 expression was a characteristic 
finding of endometrial polyps and was useful in 
differentiating between endometrial hyperplasia and 
endometrial polyps. These results are inconsistent with 
our findings that stromal p16 expression is significantly 
higher in precancerous and malignant lesions than in 
benign lesions. We observed that all endometrial polyp 
cases examined had p16 immunostaining score of ≤ 3; 
47.1% (8/17) of the endometrial polyp cases showed 
no stromal p16 expression. Moreover, 64.3% (9/14) of 
the endometrial hyperplasia cases had weak or greater 
expression. The difference in stromal p16 expression 
between endometrial polyp and hyperplasia without 
atypia was not statistically significant. On the basis of 
our data, one cannot differentiate between endometrial 
Figure 4: Stromal p16 overexpression in malignant endometrial lesions: Carcinosarcoma. A. Carcinosarcoma showing 
EC with squamous differentiation as the epithelial component. B. The stromal componentexhibits diffuse, strong p16 immunoreactivity, 
whereas the epithelial component is negative for p16. C. Carcinosarcoma showing SC as the epithelial component. D. Both the tumor cells 
(left upper corner) and stroma exhibit diffuse, strong p16 immunoreactivity.
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Table 3: Differences in stromal p16 expression between nonpathological endometrium, endometrial polyp, hyperplasia 
without atypia, AH/EIN, and EC
Category Pathological 
diagnosis
Total p16 immunostaining score P value
0 1 2 3 4 6 9
Benign Nonpathological 
endometrium
10 5 (50.0) 3 (50.0) 2 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) <0.001 (vs 
Precanceorus);
<0.001 (vs  
Malignant)
Endometrial 
polyp
17 8 (47.1) 3 (17.6) 4 (23.5) 2 (11.8) 0 (0.0) 0 (0.0) 0 (0.0)
Hyperplasia 
without atypia
14 5 (35.7) 7 (50.0) 1 (7.1) 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0)
Precancerous AH/EIN 21 1 (4.8) 3 (14.3) 4 (19.0) 5 (23.8) 6 (28.6) 2 (9.5) 0 (0.0) 0.012 (vs Malignant)
Malignant Endometrioid 
carcinoma
21 2 (9.5) 0 (0.0) 1 (4.8) 4 (19.0) 4 (19.0) 7 (33.3) 3 (14.3)
Abbreviations: AH/EIN: atypical hyperplasia/endometrioid intraepithelial neoplasia
Table 4: Differences in stromal p16 expression between atrophic endometrium, endometrial polyp, SEIC, and SC
Category Pathological 
diagnosis
Total p16 immunostaining score P value
0 1 2 3 4 6 9
Benign Atrophic 
endometrium
13 9 (69.2) 3 (23.1) 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) <0.001 (vs 
Precancerous);
<0.001 (vs  
Malignant)
Endometrial 
polyp
17 8 (47.1) 3 (17.6) 4 (23.5) 2 (11.8) 0 (0.0) 0 (0.0) 0 (0.0)
Precancerous SEIC 5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 2 (40.0) 2 (40.0) 0.788 (vs Malignant)
Malignant Serous 
carcinoma
8 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (12.5) 3 (37.5) 4 (50.0)
Abbreviations: SC: serous carcinoma, SEIC: serous endometrial intraepithelial carcinoma
Table 2: Differences in stromal p16 expression between benign, precancerous, and malignant endometrial lesions
Category Total p16 immunostaining score P value
0 1 2 3 4 6 9
Benign 62 33 (53.2) 16 (25.8) 10 (16.1) 3 (4.8) 0 (0.0) 0 (0.0) 0 (0.0) <0.001 (vs 
Precancerous);
<0.001 (vs 
Malignant)
Precancerous 26 1 (3.8) 3 (11.5) 4 (15.4) 5 (19.2) 7 (26.9) 4 (15.4) 2 (7.7) 0.005 (vs 
Malignant)
Malignant 36 2 (5.6) 0 (0.0) 1 (2.8) 4 (11.1) 6 (16.7) 14 (38.9) 9 (25.0)
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polyp and hyperplasia without atypia using stromal p16 
expression status. In addition, both EC and AH/EIN 
exhibited significantly higher stromal p16 expression 
levels compared with hyperplasia without atypia or 
endometrial polyp. This result was opposite to that of 
the previous study by Moritani et al. [28]. We attribute 
these differences to the following two reasons. First, 
two different sets of tissue samples were obtained 
from Japanese and Korean patients, and stromal p16 
expression patterns may be race-specific. Second, p16 
overexpression was observed in benign tumors such as 
benign nevus, neurofibroma, and schwannoma, which 
are related to oncogene-induced cellular senescence 
[28]. Thus, p16 overexpression in benign lesions inhibits 
cellular proliferation, protecting cells from malignant 
transformation [6]. The significantly higher rates of 
stromal p16 overexpression in endometrial polyps can 
be explained by oncogene-induced cellular senescence. 
In contrast, in this study, precancerous and malignant 
lesions showed higher levels of stromal p16 expression, 
which might be due to a positive feedback mechanism 
caused by RB protein deregulation.
Another study on p16 expression in the stroma of 
ductal carcinoma in situ (DCIS) of the breast [29] provided 
evidence that DCIS with high stromal p16 expression 
tended to show estrogen receptor negativity and high 
Ki-67 labeling indices. In addition, it was reported that 
high stromal p16 expression was a strong independent 
predictor of DCIS recurrence with a higher hazard ratio 
than the established prognostic markers. These findings 
are in agreement with our data. p16 is an inhibitor of cell 
growth in response to various stress stimuli, such as DNA 
damage, oxidative stress, or hyperproliferative signals. 
Therefore, p16 protein induces cellular senescence, such 
that stromal p16 overexpression is indicative of stromal 
cell senescence. On the basis of the results of previous 
studies, [28, 30, 31], we postulated that senescent stroma 
can contribute to disease progression by secreting 
inflammatory mediators, cytokines, and enzymes such 
as proteases, providing a mechanism through which p16-
positive stroma contributes to tumor progression and/or 
invasion.
In conclusion, we investigated the stromal 
p16 expression status in endometrial lesions by 
immunohistochemical staining. We found that stromal 
p16 expression of malignant endometrial lesions was 
significantly higher than that of precancerous lesions, 
which in turn was significantly higher than that of benign 
endometrial lesions. Stromal p16 expression was absent or 
weak in benign lesions, whereas the majority of malignant 
lesions exhibited diffuse and moderate-to-strong p16 
immunoreactivity, suggesting that stromal p16 expression 
promotes the development and progression of endometrial 
carcinoma. Further studies are necessary to confirm our 
preliminary results.
MATERIALS AND METHODS
Tissue specimens
Between March 2015 and May 2016, 124 cases 
of endometrial lesions were retrieved from the surgical 
pathology files of Severance Hospital. The pathological 
diagnoses are summarized in Table 1. The endometrial 
lesions were classified as benign, precancerous, and 
malignant in 62, 26, and 36 cases, respectively. Of the 
62 cases of benign lesions, 15 (24.2%), 10 (16.1%), 
2 (3.2%), and 35 (56.5%) cases were diagnosed 
during dilatation and curettage (D&C), hysteroscopic 
resection, total abdominal hysterectomy (TAH), and 
total laparoscopic hysterectomy (TLH), respectively. 
Of the 26 cases of precancerous lesions, 7 (26.9%), 2 
(7.7%), 2 (7.7%), 4 (15.4%), and 11 (42.3%) cases were 
diagnosed during D&C, hysteroscopic resection, robot-
assisted total hysterectomy, TAH, and TLH, respectively. 
Of the 36 cases of malignant lesions, 2 (5.6%), 2 (5.6%), 
12 (33.3), and 20 (55.6%) cases were diagnosed during 
radical abdominal hysterectomy, radical laparoscopic 
hysterectomy, TAH, and TLH, respectively. This 
study did not include any cases where the histological 
differential diagnosis between benign and precancerous 
lesions was ambiguous. None of the patients received 
preoperative neoadjuvant chemotherapy, radiation 
therapy, or concurrent chemoradiation therapy. 
Pathological diagnoses were classified following the 
criteria of the WHO Classification of Tumours of Female 
Reproductive Organs, revised in 2014 [11]. In particular, 
in the revised 2014 WHO Classification, endometrial 
Table 5: Sensitivity, specificity, positive predictive value, and negative predictive value of stromal p16 expression in 
endometrial lesions
Category Sensitivity Specificity Positive
Predictive value
Negative
Predictive value
Benign vs Precancerous/Malignant 75.61% 100.0% 100.0% 67.74%
Endometrioid Benign vs
Precancerous/Malignant
68.33% 100.0% 100.0% 53.66%
Serous Benign vs  
Precancerous/Malignant
100.0% 100.0% 100.0% 100.0%
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hyperplasia was classified into hyperplasia without atypia 
and AH/EIN on the basis of the presence of cytological 
atypia. This study was reviewed and approved by the 
Institutional Review Board at the Severance Hospital, 
Yonsei University Health System, Seoul, Republic of 
Korea (2016-1371-001).
Histopathological examination
The curetted or resected specimens were fixed 
in 10% neutral-buffered formalin and embedded in 
paraffin blocks. From each formalin-fixed, paraffin-
embedded block, 4-μm sections were cut and stained with 
hematoxylin and eosin. Two independent pathologists 
examined all available hematoxylin and eosin-stained 
slides by routine light microscopy and chose the most 
representative slide to perform immunohistochemical 
staining.
Immunohistochemical staining
The formalin-fixed, paraffin-embedded sections 
were deparaffinized and rehydrated with a xylene and 
alcohol solution. Immunohistochemical staining was 
performed using a Ventana Benchmark XT automated 
staining system (Ventana Medical Systems, Tucson, 
AZ, USA), according to the manufacturer’s instructions. 
Antigen retrieval was performed using Cell Conditioning 
Solution (CC1; Ventana Medical Systems). Sections 
were incubated with primary antibodies against p16 (pre-
diluted, clone E6H4, Ventana Medical Systems). After 
chromogenic visualization, using UltraView Universal 
DAB Detection Kits (Ventana Medical Systems), slides 
were counterstained with hematoxylin. Appropriate 
positive and negative controls were concurrently stained 
to validate the staining method.
The percentage of p16-positive stromal cells 
and the staining intensity were assessed. The cut-off 
index was defined as the presence of 10% or more cells 
displaying nuclear p16 immunoreactivity, as described 
previously [21, 28, 32]. The estimated percentages were 
categorized as follows: less than 10% (score 0), 10% to 
24% (score 1), 25% to 50% (score 2), or 50% or more 
(score 3). The staining intensity was graded as follows: 
negative (score 0), weak (score 1), moderate (score 2), or 
strong (score 3). The subcellular location of p16-positive 
signals (nuclear or cytoplasmic) was also estimated. 
The final score was calculated as the product of the 
percentage and staining intensity, resulting in scores of 
0, 1, 2, 3, 4, 6, and 9 [33].
Statistical analysis
Linear-by-linear association test was performed to 
compare the status of stromal p16 expression between 
histological types and to determine whether stromal 
p16 expression was significantly different according 
to the degree of malignancy. Statistical analyses were 
performed using PASW Statistics 18 (IBM SPSS, 
Chicago, IL, USA). Statistical significance was set at 
P < 0.05.
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